AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03503760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIMFA Therapy®
Description: It applies a packages of magneto-electric field sequences having variable geometry, with frequencies and intensities that vary in a range of 0-80 Hertz and 0-100 microTesla, respectively.
Study NCT04282707 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic closure of ESD defect
Description: Closure of ESD defect would be performed with clip loop purse string technique
Study NCT04282707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gastric ESD without closure of ESD defect
Description: Historical control with patients undergoing ESD without closure of ESD defect
Study NCT01598467 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Robotic assisted sacrocolpopexy (RASC)
Description: Robotic assisted sacrocolpopexy (RASC) will be performed with the Da Vinci Surgical robot (Intuitive Surgical). THe mesh used will be a Type I (Amid classification), polypropylene mesh
Study NCT02234804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience Prime Stent
Study NCT02234804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xience Prime Stent
Study NCT02234804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Resolute Integrity stent
Study NCT02234804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Resolute Integrity stent
Study NCT02234804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angiography
Study NCT02234804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography
Study NCT03722641 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Product 2: Full fat milk + oat
Description: Developed product based on full fat milk with addition of oat
Study NCT03722641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 2: Full fat milk + oat
Description: Developed product based on full fat milk with addition of oat
Study NCT03804866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m² iv every 3 weeks for a maximum of 8 cycles
Study NCT02936258 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).
Study NCT02936258 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
Study NCT02936258 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI Targeted Biopsy
Description: Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
Study NCT03722641 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Product 3: Skim milk + oat, high fibre
Description: Developed product based on skim milk with addition of oat giving a high fiber content to the product
Study NCT03722641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 3: Skim milk + oat, high fibre
Description: Developed product based on skim milk with addition of oat giving a high fiber content to the product
Study NCT00265824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: bevacizumab 7.5mg/kg every 3 weeks until disease progression or limiting toxicity
Study NCT00265824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab, erlotinib
Description: bevacizumab 7.5mg/kg and oral erlotinib 150 mg/day continuously Cycles every 3 weeks until disease progression or limiting toxicity
Study NCT03224702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6495
Description: Subjects will receive M6495 on Day 1
Study NCT03224702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matched to M6495 on Day 1
Study NCT03722641 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Product 4: Skim milk + oat, low fibre
Description: Developed product based on skim milk with addition of oat giving a lower fiber content to the product
Study NCT03722641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 4: Skim milk + oat, low fibre
Description: Developed product based on skim milk with addition of oat giving a lower fiber content to the product
Study NCT01700894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Program + Motivational Interviewing Calls
Study NCT01700894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Program + Automated Calls
Study NCT01700894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Program
Study NCT02267421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home based Aerobic exercise training
Study NCT03165851 — intervention group
Intervention type: OTHER
Intervention: Risk-stratified therapy
Description: Dose-dense intensive chemotherapy and high dose of Ara-C in the consolidation therapy.
Study NCT04178330 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: Whole brain radiation (WBRT) with 38-40Gy in 20 fractions and concurrent boost of 60-70Gy of the lesions. TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles.
Study NCT03343665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 40 mg in 4 ml Injection
Description: 40 mg by intravenous (IV) infusion on day 1 Duration of cycle 14 days
Study NCT01326312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-758 1000mg
Description: comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
Study NCT01326312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupron Depot
Description: comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
Study NCT01326312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-758 2000mg
Description: comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
Study NCT03164967 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bivigam
Study NCT04382911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluoroestradiol
Description: Patients will receive the FES tracer during a PET/MRI scan
Study NCT02394080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photodynamic Bone Stabilization System
Description: Treatment of acute humerus fractures
Study NCT02234804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCT
Study NCT02234804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OCT
Study NCT02583854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RY-STOP hemostasis device
Study NCT02583854 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TR-Band, Terumo
Study NCT01733758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg weekly
Description: Albiglutide will be available as a pen injector that delivers 30mg of albiglutide
Study NCT01733758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide 50 mg weekly
Description: Albiglutide will be available as a pen injector that delivers 50mg of albiglutide
Study NCT01733758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Albiglutide matching placebo will be available as a pen injector
Study NCT01733758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Albiglutide matching placebo will be available as a pen injector
Study NCT01733758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide 0.9 mg daily
Description: Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose
Study NCT01558466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 50 mg tablet will be thoroughly crushed into powder form and diluted in 10 ml ora base suspension syrup agent and a dilution will be performed to prepare 5 mg/ml. All doses required for 48 hours will be available; solutions will be stored at 2-8 degrees C where solution should be stable for at least a month.
Study NCT01558466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: diluent
Description: The placebo will have an equal volume of diluent - Orabase syrup of the same colour and viscosity as the active comparator. Infants in this group will receive normal saline as placebo every 6 hours
Study NCT03215134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-criticism intervention
Description: Compassion Focused Therapy (Gilbert, 2010) adapted to focus specifically on reducing self-criticism. This intervention was originally developed for a student population (Rose, McIntyre \& Rimes, submitted) and is now being evaluated in a primary mental-health service.
Study NCT05581316 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Patients' procalcitonin, thrombocyte, and leukocyte levels were assessed every other day for 4 weeks, beginning on the first day they were admitted to the burn center.
Description: This patients who were included in this study were assessed for four weeks from the first day of hospitalization and taken to the treatment program. All patients who use peripheral venous catheters in this group.
Study NCT02765204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Study NCT00990366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cook´s biliary stent with an antireflux stent, normal biliary stent
Description: arms are assigned randomly by closed envelope method
Study NCT00382434 — intervention group
Intervention type: PROCEDURE
Intervention: presence of an emergency pharmacist in the ED
Study NCT03769038 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: chronic total occlusion
Description: chronic total occlusion of coronary atery was opened and then stents were placed
Study NCT00558116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic splinting
Description: The Dynasplint carpal tunnel device will be worn for 30 minutes, twice daily, for 60 consecutive days.
Study NCT00558116 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Dynamic splinting
Description: The Dynasplint carpal tunnel device will be worn for 30 minutes, twice daily, for 60 consecutive days.
Study NCT03489889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid 300mg tablet
Description: Cross-over study: Ursodeoxycholic Acid 300mg tablet and after Ursodeoxycholic Acid 300mg capsule
Study NCT03489889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid 300mg capsule
Description: Cross-over study: Ursodeoxycholic Acid 300mg capsule and after Ursodeoxycholic Acid 300mg tablet
Study NCT03315039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Annamycin
Description: 2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
Study NCT00696332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: capsules Talampanel, 3 times per day, 52 weeks
Study NCT00696332 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules, placebo, 3 times a day, for 52 weeks
Study NCT04100759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg Oral Tablet
Description: Sildenafil 50 mg Oral Tablet
Study NCT04120961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prolonged continuous use of bivalirudin
Description: prolonged continuous use of bivalirudin 4 hours after elective PCI (dose: 0.75 mg/kg bolus plus 1.75 mg/kg per hour)
Study NCT04120961 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bivalirudin use during ePCI
Description: bivalirudin use during ePCI (0.75 mg/kg bolus plus 1.75 mg/kg per hour)
Study NCT00894868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Study NCT00894868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of vildagliptin
Study NCT02336672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryothermal ablation
Description: Procedures are performed with patients sedated by anaesthesiologists. Device setting and application time are set and recorded on a computer, that analyzes the changes of the tissue's properties. The setting of the maximal application time is based on the results of our previously described ex-vivo and in-vivo studies and is adjusted to the tumour's size, thus ensuring a reduction of procedure-related complications. Application of Power Doppler makes the procedure safer. The HybridTherm probe is guided under real-time EUS into the tumour, and the success of its placement is an index of the treatment's feasibility. The system analyzes the effects on the tissue and EUS records the changes of the tissue, the growing edema around the treated area, and the tissue devitalization.
Study NCT03187444 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Examinations
Description: Several examinations are realized on each patients, in addition to the usual visit and after verification of the criteria of inclusion and signature of consent.
Study NCT05318404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jejunostomy feeding
Description: Maintain jejunostomy feeding till postoperative 1st visit after esophagectomy in delayed feeding group
Study NCT03101501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin c
Description: Low dose mitomycin C at a concentration of 0.02% will be applied a duration of 10 to 30 seconds at the time of the surgical procedure.
Study NCT03101501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raindrop Near Vision Inlay
Description: Implanted to improve near vision in Presbyopic or Pseudophakic subjects.
Study NCT02703324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered subcutaneously (SC)
Study NCT02703324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study NCT04381169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer Solution
Description: Comparison of aggressive versus moderate Lactated Ringer-based fluid resuscitation
Study NCT04381663 — intervention group
Intervention type: PROCEDURE
Intervention: conservative treatment
Description: conservative treatment for patients with cervical spine stenosis without myelopathy
Study NCT04381663 — intervention group
Intervention type: PROCEDURE
Intervention: surgical treatment
Description: surgical decompress the spinal canal in patients with moderate to severe degenerative cervical spine myelopathy
Study NCT04910035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises Training
Description: SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
Study NCT03492541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propylene glycol-based eye drops
Description: Nano-emulsion ocular lubricant
Study NCT02708810 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Unframed Virtual Cone
Description: A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. This will allow for very precise targeting. During the procedure, the study doctor will also confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask (unframed) will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on the painful nerve in the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is in the range of 30 to 60 minutes. The face mask (unframed) will be removed after the treatment.
Study NCT02708810 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 80 Gy Radiation
Study NCT01436786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
Study NCT00003515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT00856765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting balloon
Description: Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
Study NCT00856765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bare metal stent
Description: Bare metal stent
Study NCT00856765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare metal stent
Description: Bare metal stent
Study NCT00856765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug eluting stent
Description: Paclitaxel eluting stent
Study NCT00894361 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TKA surgery with the rotating platform mobile-bearing knee design
Description: Depuy Sigma RP rotating platform design
Study NCT00894361 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TKA surgery with the all-polyethylene tibia knee design
Description: Depuy Sigma fixed-bearing design with all-polyethylene tibia
Study NCT02765204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Study NCT02813239 — intervention group
Intervention type: OTHER
Intervention: hCG
Description: Oocyte maturation with hCG
Study NCT03160092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention aims to:~* Support the participant to explore their unusual experiences~* Reduce the distress or anxiety participants feel in response to their unusual experiences, through:~  * Helping them to recognise how common these unusual experience~ * Supporting them to make sense of their unusual experiences~ * Supporting them to understand why they may be experiencing these symptoms~ * Challenging any unhelpful beliefs they hold about their symptoms~* Help the participant to recognise the triggers to their unusual experiences~* Support the participant to increase their activities and socialisation~The intervention is not aiming to 'get rid' of the participant's symptoms, but to reduce their distress in response to them, which may result in improved wellbeing and reduced symptoms.
Study NCT03214016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: 1 hour of aerobic training on a treadmill, 3 times a week, during 8 weeks.
Study NCT02813239 — intervention group
Intervention type: OTHER
Intervention: hCG + GnRH agonist
Description: Oocyte maturation with hCG + GnRH agonist
Study NCT01552863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation A, single dose
Study NCT01552863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation E, single dose
Study NCT02765204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Study NCT03529435 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Massed Prolonged Exposure
Description: Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks. If necessary, the treatment window may be extended for another week.
Study NCT03529435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Outpatient Prolonged Exposure
Description: The IOP-PE will include the same primary treatment components as the Massed-PE protocol (fifteen weekday 90-minute PE sessions delivered five days a week over a three-week period) plus eight augmentations designed to maximize treatment outcomes. Similar to the Mass-PE, participants will have three consecutive weeks to complete treatment; however, the treatment window may be extended another week if necessary.
Study NCT04812977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A
Description: Combination of intravitreal triamcinolone acetonide (Kenacort-AⓇ) (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml)